DOCSLIB.ORG

Ep 2326341 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

(19) & (11) EP 2 326 341 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38/11 (2006.01) 04.07.2012 Bulletin 2012/27 (86) International application number: (21) Application number: 09788312.8 PCT/NL2009/050542 (22) Date of filing: 09.09.2009 (87) International publication number: WO 2010/030180 (18.03.2010 Gazette 2010/11) (54) Oxytocin formulations and uses thereof Oxytocin-Formulierungen und ihre Verwendungen Formulations d’oxytocine et leur utilisations (84) Designated Contracting States: • TRISSEL ET AL: INTERNATIONAL JOURNAL OF AT BE BG CH CY CZ DE DK EE ES FI FR GB GR PHARMACEUTICAL COMPOUNDING, vol. 10, HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL 2006, pages 156-158, XP002513262 cited in the PT RO SE SI SK SM TR application • BOOTHBY ET AL: "Extended stability of oxytocin (30) Priority: 09.09.2008 EP 08163932 in Ringer’s lactate solution at 4° and 25°C" HOSPITAL PHARMACY, vol. 41, 2006, pages (43) Date of publication of application: 437-441, XP002513263 01.06.2011 Bulletin 2011/22 • DE GROOT ET AL: "Oxytocin and desamino- oxytocin tablets are not stable under simulated (73) Proprietor: Rijksuniversiteit Groningen tropical conditions" JOURNAL OF CLINICAL 9712 CP Groningen (NL) PHARMACY AND THERAPEUTICS, vol. 20, 1995, pages 115-119, XP002513264 cited in the (72) Inventors: application • AMORIJ, Jean-Pierre • WYTTENBACH ET AL: "Interactions of the NL-1544 PA Zaandijk (NL) hormone oxytocin with divalent metal ions" • AVANTI, Christina JOURNAL OF THE AMERICAN CHEMICAL NL-9725 AN Groningen (NL) SOCIETY, vol. 130, May 2008 (2008-05), pages • FRIJLINK, Henderik, Willem 5993-6000, XP002513366 NL-9761 KM Eelde (NL) • BAL ET AL: "Potentiometric and spectroscopic • HINRICHS, Wouter, Leonardus, Joseph studies of the Cu(II) complexes of Ala-Arg NL-9718 EG Groningen (NL) (8)-vasopressin and oxytocin: Two vasopressin- like peptides" JOURNAL OF INORGANIC (74) Representative: Jansen, Cornelis Marinus et al BIOCHEMISTRY, vol. 45, 1992, pages 193-202, VEREENIGDE XP002513265 Johan de Wittlaan 7 • ANANTHANARAYANAN ET AL: "Interaction of 2517 JR Den Haag (NL) oxytocin with Ca(2+): I. CD and fluorescence spectral characterization and comparison with (56) References cited: vasopressin" BIOPOLYMERS, vol. 40, 1996, MX-A- 9 707 899 pages 433-443, XP002513367 • SLANINOVÁ ET AL: "Oxytocin, divalent cations • KALIS ET AL: LATVIJAS PSR ZINATNU and mechanism of action" JOURNAL OF AKADEMIJAS VESTIS, KIMIJAS SERIJA, vol. 29, PEPTIDE SCIENCE, vol. 12, no. S1, 2006, page no. 1, 1970, pages 29-32, XP008101303 cited in 404, XP002590740 the application Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 326 341 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 2 326 341 B1 • LIU ET AL: "Oxytocin-receptor binding: Why • BRASUNET AL: "Histidine analoguesof oxytocin divalent metals are essential" JOURNAL OF THE andvasopressin as efficient ligands for Zn2+ ions AMERICAN CHEMICAL SOCIETY, vol. 127, 2005, - potentiometric and NMR studies" JOURNAL OF pages 2024-2025, XP002590741 INORGANIC BIOCHEMISTRY, vol. 103, 10 May 2009 (2009-05-10), pages 1033-1038, XP026218206 2 EP 2 326 341 B1 Description [0001] The present invention relates to the field of preventive and therapeutic medicine. In particular, it relates to therapeutic formulations comprising disulfide bridge-containing neurohypophysial nonapeptides, such oxytocin, vaso- 5 pressin or analogs thereof. Provided are heat-stable oxytocin formulations and uses thereof in indications such as induction of labor, augmentation of labor, post-partum haemorrhage or uterine atony. Also provides are heat-stable vasopressin formulations and uses thereof in indications such as diabetes insipidus and vasodilatory shock. [0002] Oxytocin (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) and vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg- Gly-NH2) are peptide hormones that are produced in the brain of most mammals, including humans, and that share a 10 high degree of homology. Both nonapeptides originate from the same evolutionary progenitor, vasotocin (Cys-Tyr-Ile- Gln-Asn-Cys-Pro-Arg-Gly-NH2). Their respective amino acid sequences differ only at position 3 (Ile versus Phe) and position 8 (Leu versus Arg). Both peptides contain a sulfur bridge that is formed by the cysteine residues at positions 1 and 6. [0003] Next to their structural resemblance, there is also an anatomical relationship between oxytocin and vasopressin 15 (also known as arginine vasopressine (AVP), argipressin and anti-diuretic hormone (ADH)). For example, in most species the genes for these peptides are located on the same chromosome and are separated by a relatively small distance of less than 15.000 bases. Also, the hypothalamic magnocellular neurons that synthesize oxytocin are located adjacent to those that synthesize vasopressin, and are similar in many respects. [0004] Furthermore, it is known that the structural similarity of these hormones causes some functional cross- reactions 20 in the body: whereas oxytocin has a slight antidiuretic function, high levels of vasopressin may cause uterine contractions. [0005] Oxytocin, vasopressin and analogues thereof are widely used in human and veterinarian medicine. Vasopressin is mainly applied for treatment of diabetes insipidus and vasodilatory shock, the latter occurring for example during sepsis, organ transplantation or after implantation of a cardiopulmonary bypass. It is commercially available as either generic vasopressin or synthetic analogues, such as desmopressin (1-desamino-8-D-arginine vasopressin or DDAVP; 25 trade names Stimate®, Minirin® and Octostim®) and terlipressin (trade name Glypressin®). Oxytocin is often used to induce labor and support labor in case of non- progression of parturition and to treat (post-partum) haemorrhage. Currently, oxytocin is considered to be the principal agent to treat post- partum haemorrhage. It is degraded in the gastrointestinal tract, therefore it is administered as aqueous formulation by injection or as nasal spray. Its half-life in the blood is typically about three minutes. Synthetic oxytocin is commercially available as ready- to-use aqueous formulations under the trade 30 names Pitocin® and Syntocinon® or as generic oxytocin. The oxytocin analogues desamino-oxytocin and carbetocin (trade name Duratocin®) are also commercially available. [0006] According to the World Health Report 2005 as issued by the World Health Organization, in Africa, Asia and Latin America each year half a million women die as a result of problems during pregnancy and childbirth. In Africa and Asia, at least 25% of those deaths can be attributed to haemorrhage, most commonly caused by failure of the uterus to 35 contract adequately after childbirth (atonicity). This makes haemorrhage the leading cause of maternal deaths in these continents (Khan et al., Lancet 367 (9516): 1066-1074, 2006). In third world countries, it is often practically and/or economically impossible to protect pharmaceutical preparations from the harmful effects of high temperatures during transportation, storage and use. Reports and stability studies of injectable oxytocins have shown serious instability on exposure to increased temperatures and exposure to light (see de Groot et al., World Health Organization, WHO/DAP/ 40 94.13, 1994 and de Groot et al., J Clin Pharm Ther 20 (2): 115-119, 2008, and references cited therein). The 1994 publication by de Groot et al. discloses that tablets of oral oxytoxin or analogs thereof (also referred to as oxytocics) such as ergometrine, methylergometrine, oxytocin and desamino-oxytocin, are not stable under simulated tropical con- ditions, and concludes that oral oxytocins are not suitable for use in the prevention of postpartum haemorrhage. Thus, despite the availability of various formulations of oxytocin and desamino-oxytocin for treatment of haemorrhage, the 45 (sub)tropical ambient temperatures and the absence of a so- called cold-chain in these parts of the world severely affect their stability and functionality. Proper prophylaxis and / or treatment of haemorrhage is therefore nearly impossible, resulting in this astonishingly high number of casualties each year. Vasopressin formulations known to date are similarly affected by exposure to high ambient temperature or light. [0007] Given the reduced stability of formulations comprising bioactive or therapeutic peptides such as oxytocin or 50 vasopressin at increased temperatures, their use in treatment methods in (sub)tropical countries, including many third world countries, is limited. Thus, there is a clear need for peptide formulations, preferably as a ready-to-use injectable aqueous solution, that have an improved thermal stability. [0008] One object of the invention to provide means and methods to increase the thermal stability of aqueous formu- lations comprising oxytocin, vasopressin or an analogue thereof. A further object is the provision of a therapeutic or 55 prophylactic oxytocin- or vasopressin- formulation, e.g. a ready-to- use medication that can be administered to a subject in need thereof, that has a stability that can withstand (sub)tropical ambient temperatures,
Recommended publications
  • (1982), 24(4), 329—337 Pineal Response to Lithium1

    (1982), 24(4), 329—337 Pineal Response to Lithium1

    Indian J. Psychiat. (1982), 24(4), 329—337 PINEAL RESPONSE TO LITHIUM1 S. PARVATHI DEVI* A. VENKOBA RAO> PINEAL FUNCTION AND BEHAVIOUR—A until Crowther demonstrated from his REVIEW autopsy studies that pineal calcification The pineal gland in ma.i is an active had nothing to do with mental derange­ endocrine gland throughout life (Wurtman ment. et al., 1964 ; Tapp & Huxley, 1972 ; Interest in the pineal gland lay dormant Cardinali, 1974 ; Reiter et al., 1975 ; Reiter, and the gland was relegated to be a ves- 1978). It elaborates several hormones with tigeal organ until the endocrine nature precise rhythmicity. The chronobiological of the gland was suggested following des­ aspects of the mammalian pineal gland have criptions of pineal tumours associated with been clearly brought out by Reiler (198!) precocious puberty (Kitay, 1954). The defining the circadian rhythms in indole idea of a special relation of pineal gland to metabolism within the pineal of mammals. mind was revived in reports of experiments The two major classes of pineal hormones— with pineal extracts in the treatment of pineal indoles (melatonin, serotonin and schizophrenia (Becker, 1920 ; Eldered et the tryptophols) and the polypeptides are al., 196U; Kitay & Altschule, 1954). The known to influence several physiological isolation and characterisation of the pineal systems including the central nervous system hormone melatonin was a turning point (Cardinali, 1974 and Anton Tay, 1974). in pineal research (Lerner et al., 1958). The association of pineal gland with be­ Since then the pineal gland has been a haviour and mental illness can be traced to focus of intense scientific enquiry revealing Alexandrian school of thought (Herophilus it to be an endocrine gland capable of c.
  • Us Anti-Doping Agency

    Us Anti-Doping Agency

    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
  • The Oxytocin/Vasopressin Receptor Family Has at Least Five Members in the Gnathostome Lineage, Including Two Distinct V2 Subtypes

    The Oxytocin/Vasopressin Receptor Family Has at Least Five Members in the Gnathostome Lineage, Including Two Distinct V2 Subtypes

    The oxytocin/vasopressin receptor family has at least five members in the gnathostome lineage, including two distinct V2 subtypes General and Comparative Endocrinology 175(1): 135-143 doi:10.1016/j.ygcen.2011.10.011 Accepted October 20, 2011 E-pub October 28, 2012 Published January 1, 2012 Figshare doi:10.6084/m9.figshare.811860. Shared October 1, 2013 Daniel Ocampo Daza*, Michalina Lewicka¹, Dan Larhammar Department of Neuroscience, Science for Life Laboratory, Uppsala Universitet, Box 593, SE-751 24 Uppsala, Sweden * Corresponding author. E-mail address: [email protected] ¹ Current address: Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden Cite as D. Ocampo Daza, M. Lewicka and D. Larhammar. The oxytocin/vasopressin family has at least five members in the gnathostome lineage, including two distinct V2 subtypes. General and Comparative Endocrinology, 175 (1) (2012) 135-143. This document corresponds to the article as it appeared upon acceptance. You are free to download, print and distribute it for any purposes under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/), provided the original work is cited as specified. Errata: The introduction incorrectly states that “the V2 receptor inhibits adenylyl cyclase, thereby reducing the production of cAMP” on page 3. In fact the V2-type vasopressin receptors stimulate adenylyl cyclase and increase the cytosolic cyclic AMP release, see for instance Schöneberg et al., Molecular aspects of vasopressin receptor function, Advances in experimental medicine and biology 449 (1998) 347–58. This mistake was reported in the proofreading phase of pre-publication, but the correction was not carried to the final version of the article.
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands

    Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    1 Advances in Therapeutic Peptides Targeting G Protein-Coupled

    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • The V2 Receptor Antagonists

    The V2 Receptor Antagonists

    REVIEW New Horizons in the Pharmacologic Approach to Hyponatremia: The V2 Receptor Antagonists Biff F. Palmer, MD Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. Disclosure: B.F. Palmer received an honorarium funded by an unrestricted educational grant from Otsuka America Pharmaceuticals, Inc., for time and expertise spent in the composition of this article. No editorial assistance was provided. He also receives speaker fees from Otsuka America Pharmaceuticals, Inc. This article provides an overview of the developing niche for vasopressin 2 receptor antagonists (‘‘vaptans’’) in the management of hyponatremia in clinical practice. Specific areas of focus include the physiological and clinical rationale for use of this class of medications (including advantages over older and less specific therapeutic modalities), the practical limitations to the use of these new drugs (including issues of tolerability, toxicity, risk, and cost), and the unanswered question of the extent to which correcting hyponatremia will improve clinical outcomes. Journal of Hospital Medicine 2010;5:S27–S32. VC 2010 Society of Hospital Medicine. KEYWORDS: arginine vasopressin, AVP receptor antagonists, conivaptan, tolvaptan, hyponatremia. Under normal circumstances, there is a balance between pressure or blood volume have no effect on AVP levels. water intake and water excretion such that plasma osmolal- However, once decreases in volume or pressure exceed this ity and the serum sodium (Naþ) concentration remain rela- value, baroreceptor-mediated signals provide persistent tively constant. The principal mechanism responsible for stimuli for AVP secretion. Baroreceptor-mediated AVP prevention of hyponatremia and hyposmolality is renal release will continue even when plasma osmolality falls water excretion.
  • Fluorescent Agonists and Antagonists for Vasopressin/Oxytocin G Protein-Coupled Receptors: Usefulness in Ligand Screening Assays and Receptor Studies

    Fluorescent Agonists and Antagonists for Vasopressin/Oxytocin G Protein-Coupled Receptors: Usefulness in Ligand Screening Assays and Receptor Studies

    Fluorescent agonists and antagonists for vasopressin/oxytocin g protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Bernard Mouillac, Maurice Manning, Thierry Durroux To cite this version: Bernard Mouillac, Maurice Manning, Thierry Durroux. Fluorescent agonists and antagonists for vasopressin/oxytocin g protein-coupled receptors: usefulness in ligand screening assays and receptor studies.. Mini-Reviews in Medicinal Chemistry, Bentham Science Publishers, 2008, 8 (10), pp.996- 1005. 10.2174/138955708785740607. inserm-00323511 HAL Id: inserm-00323511 https://www.hal.inserm.fr/inserm-00323511 Submitted on 22 Mar 2009 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors!: usefulness in ligand screening assays and receptor studies. B. Mouillac1,*, M. Manning2 and T. Durroux1,* 1CNRS, UMR5203, Institut de Génomique Fonctionnelle, Montpellier, FRANCE and INSERM, U661, Montpellier, FRANCE and Universités de Montpellier I, II, Montpellier, FRANCE. 2Department of Biochemistry and Cancer Biology, University of Toledo, College of Medicine, Toledo, Ohio 43614, USA. *To whom correspondence should be addressed!: [email protected], [email protected]. Institut de Génomique Fonctionnelle, Département de Pharmacologie Moléculaire, CNRS UMR5203, INSERM U661, 141 rue de la cardonille, 34094 Montpellier cedex 05, FRANCE.
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
  • List of Pharamaceutical Peptides Available from ADI

    List of Pharamaceutical Peptides Available from ADI

    List of Pharamaceutical Peptides Available from ADI ADI has highly purified research grade/pharma grade pharmaceutical peptides available for small research scale or in bulk (>Kg scale). (See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2704 Catalog# Product Description Catalog# Product Description PP-1000 Abarelix (Acetyl-Ser-Leu-Pro-NH2; MW:1416.06) PP-1410 Growth Hormone-releasing factor, GRF (human) PP-1010 ACTH 1-24 (Adrenocorticotropic Hormone human) Acetate PP-1420 Hexarelin PP-1020 Alarelin Acetate PP-1430 Histrelin Acetate PP-1030 Angiotensin PP-1440 Lepirudin PP-1040 Angiotensin II Acetate PP-1450 Leuprolide PP-1050 Antide Acetate PP-1460 Leuprorelin Acetate PP-1060 Argipressin Acetate PP-1470 Lipopeptide Acetate PP-1070 Argireline Acetate PP-1480 Lypressin PP-1080 Atosiban Acetate PP-1490 Lysipressin Acetate PP-1090 Aviptadil PP-1500 Matrixyl Acetate PP-1100 Bivalirudin Trifluoroacetate PP-1510 Melanotan I, Acetate PP-1110 Buserelin acetate PP-1520 Melanotan II, MT-II, Acetate PP-1120 Copaxone acetate (Glatiramer acetate) PP-1530 Mechano Growth Factor, MGF, TFA PP-1130 Carbetocin acetate PP-1540 Nafarelin Acetate PP-1140 Cetrorelix Acetate PP-1550 Nesiritide Acetate PP-1150 Corticotropin-releasing factor, CRF (human, rat) Acetate PP-1560 Octreotide Acetate PP-1160 Corticotropin-releasing factor, CRF (ovine) PP-1570 Ornipressin Acetate Trifluoroacetate PP-1580 Oxytocin Acetate PP-1170 Deslorelin Acetate PP-1590 Palmitoyl Pentapeptide PP-1180 Desmopressin Acetate PP-1610 Pentagastrin Ammonium
  • Queensland Health List of Approved Medicines

    Queensland Health List of Approved Medicines

    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.